3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 1
1
Status
Recruiting
2
Active not recruiting
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
NET
3
Endocrine
3
Sarcoma
1
Lymphoid
1
Gastrointestinal
1
CNS
1
Conditions
Neuroendocrine Tumors
3
Thymus Neoplasms
1
Rhabdomyosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Lymphoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Central Nervous System Neoplasms
1
Interventions
lutetium Lu 177 dotatate
12
Specimen Handling
6
Magnetic Resonance Spectroscopy
6
pembrolizumab
5
cabozantinib
5
Everolimus
5
Nivolumab
4
olaparib
3
lenvatinib
3
Cyclophosphamide
3
177Lu-octreotide, DOTA(0)-Tyr(3)-
3
lanreotide
2
gallium Ga 68 dotatate
2
fludarabine phosphate
2
fludarabine
2
avelumab
2
amino-acid, glucose, and electrolyte solution
2
X-Rays
2
Radiotherapy
2
Phantoms, Imaging
2
Octreotide
2
Lutetium-177
2
Ipilimumab
2
Etoposide
2
Cisplatin
2
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
2
telotristat ethyl
1
surufatinib
1
repotrectinib
1
peposertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
177Lu-octreotide, DOTA(0)-Tyr(3)-
×
90 days
×
Clear all
NCT05918302
2026-05-12
LEVEL
Grupo Espanol de Tumores Neuroendocrinos
Phase 3
Recruiting
170 enrolled
NCT06441331
2026-05-01
KinLET
ITM Solucin GmbH
Phase 1
Recruiting
20 enrolled
NCT03049189
2026-04-06
COMPETE
ITM Solucin GmbH
Phase 3
Active not recruiting
324 enrolled
15 charts